PepsiCo CEO: Urgent Fixes Needed for Soft Drinks Business -- WSJ
Dow Jones2026/10/08 14:01By Laura Cooper PepsiCo's CEO said his company is losing the beverage wars. Ramon Laguarta said PepsiCo isn't competing well in soft drinks, including its flagship Pepsi. It plans to put "all the urgency of the business and the focus on improving our performance in soft drinks," he said on a conference call. The plan includes increasing investment behind recently acquired prebiotic soda brand Poppi as well as Mountain Dew and Pepsi. The company is focused on cutting costs and investing those savings back into the beverage business, he said. This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL (WSJ Live Coverage). (END) Dow Jones Newswires October 08, 2026 10:01 ET (14:01 GMT)
By Laura Cooper
PepsiCo's CEO said his company is losing the beverage wars.
Ramon Laguarta said PepsiCo isn't competing well in soft drinks, including its flagship Pepsi. It plans to put "all the urgency of the business and the focus on improving our performance in soft drinks," he said on a conference call.
The plan includes increasing investment behind recently acquired prebiotic soda brand Poppi as well as Mountain Dew and Pepsi. The company is focused on cutting costs and investing those savings back into the beverage business, he said.
This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL (WSJ Live Coverage).
(END) Dow Jones Newswires
October 08, 2026 10:01 ET (14:01 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Morgan Stanley raises CME Group price target to $337
Chip design software leader Synopsys seeks collaboration with Chinese large model laboratories

Former BioNTech executive leads Bambusa Therapeutics (BBTX.US) in sprint to Nasdaq, "boosting" eczema drug trials
Bambusa Therapeutics Inc. has filed for an initial public offering, planning to raise funds for clinical trials of treatments for eczema and other inflammatory diseases.